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Background
Von Willebrand´s disease (VWD) is the most common
congenital disorder of hemostasis, characterized by defi-
cient or defective von Willebrand factor. Patients are trea-
ted by intravenous replacement of factor VIII/VW (FVIII/
VW) when needed, for prophylaxis before surgical proce-
dures. Anaphylactic reactions to FVIII/VW are rare and
desmopressin (DDAVP) can be used as an alternative.
Materials and methods
We report a case of a 16-year-old female, with VWD and
no personal or family history of atopic disease, that was
referred to our unit after 4 episodes of facial, upper and
lower extremities urticaria, 30 minutes after infusion of
FVIII/VW. She has been treated with the factor since
2000, and had her first allergic reaction in 2004. After the
first episode, she received pretreatment with oral dex-
chlorpheniramine and hydrocortisone IV. The last episode
was in March 2013, when she had laryngeal edema, which
required epinephrine. The factor was replaced by DDAVP,
but she developed itching, flushing and hypertension. We
evaluated the patient using the ENDA questionnaire and
skin tests. Skin prick test (SPT) to FVIII/VW (Octavi®
SDOptimum; Octapharma, Vienna, Austria) was per-
formed at full-strength concentration (50 U/ml) with his-
tamine as positive control and normal saline as negative
control. Intradermal skin tests (ID) were performed with
1:1000, 1:100, 1:10 and 1:1 concentrations. The reactions
were assessed at 15 minutes. Her mother served as control
subject and gave informed consent before testing and
desensitization. A desensitization protocol was designed
for the patient. Briefly, intravenous infusions of FVIII/
FVW were started at 0.01 U/kg and doses were doubled at
10-minute intervals initially and then at 15-minute inter-
vals to reach a cumulative dose of 30 U/ml. She was pre-
medicated with diphenhydramine 25 mg, ranitidine 50 mg
and montelukast 10 mg.
Results
SPT were negative in both patient and control subject.
ID reactions at all dilutions were negative in control
subject but it was positive at 1:1000 dilution in the
patient (wheal of 8 mm). She developed an urticarial
rash 4 hours after skin tests, treated with fexofenadine.
Four days later, she underwent successful desensitization
which was completed in 2 hours and 35 minutes.
Conclusions
Rapid desensitization for FVIII/VW induced anaphylaxis
should be considered in patients with VWD to allow for
safe surgical procedures.
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